MYD88 and ovarian cancer: Our group and others have previously demonstrated that TLR4, MyD88 and MAD2 play key roles in paclitaxel resistance in ovarian cancer and are associated with poor patient outcome [3, 4, 6–9, 11–13, 15, 16, 24, 25, 33–36].